The aim of the present study was to clarify whether cotinine affects the release of catecholamines (CA) from the isolated perfused rat adrenal gland, and to establish the mechanism of its action, in comparison with the response of nicotine. Cotinine (0.3∼3 mM), when perfused into an adrenal vein for...
The aim of the present study was to clarify whether cotinine affects the release of catecholamines (CA) from the isolated perfused rat adrenal gland, and to establish the mechanism of its action, in comparison with the response of nicotine. Cotinine (0.3∼3 mM), when perfused into an adrenal vein for 60 min, inhibited CA secretory responses evoked by ACh (5.32 mM), DMPP (a selective neuronal nicotinic agonist, 100 $\mu$M for 2 min) and McN-A-343 (a selective muscarinic $M_1 -agonist, 100 \mu$ M for 2 min) in dose- and time-dependent manners. However, cotinine did not affect CA secretion by high $K^+$ (56 mM). Cotinine itself also failed to affect basal CA output. Furthermore, in the presence of cotinine (1 mM), CA secretory responses evoked by Bay-K-8644 (an activator of L-type $Ca^{2+}$ channels, 10 $\mu$ M) and cyclopiazonic acid (an inhibitor of cytoplasmic $Ca^{2+}-ATPase, 10 \mu$ M) were relative time-dependently attenuated. However, nicotine (30$\mu$ M), given into the adrenal gland for 60 min, initially rather enhanced CA secretory responses evoked by ACh and high $K^+$, followed by the inhibition later, while it time-dependently depressed the CA release evoked by McN-A-343 and DMPP. Taken together, these results suggest that cotinine inhibits greatly CA secretion evoked by stimulation of cholinergic (both nicotinic and muscarinic) receptors, but does fail to affect that by the direct membrane-depolarization. It seems that this inhibitory effect of cotinine may be exerted by the cholinergic blockade, which is associated with blocking both the calcium influx into the rat adrenal medullary chromaffin cells and $Ca^{2+}$ release from the cytoplasmic calcium store. It also seems that there is a big difference in the mode of action between cotinine and nicotine in the rat adrenomedullary CA secretion.
The aim of the present study was to clarify whether cotinine affects the release of catecholamines (CA) from the isolated perfused rat adrenal gland, and to establish the mechanism of its action, in comparison with the response of nicotine. Cotinine (0.3∼3 mM), when perfused into an adrenal vein for 60 min, inhibited CA secretory responses evoked by ACh (5.32 mM), DMPP (a selective neuronal nicotinic agonist, 100 $\mu$M for 2 min) and McN-A-343 (a selective muscarinic $M_1 -agonist, 100 \mu$ M for 2 min) in dose- and time-dependent manners. However, cotinine did not affect CA secretion by high $K^+$ (56 mM). Cotinine itself also failed to affect basal CA output. Furthermore, in the presence of cotinine (1 mM), CA secretory responses evoked by Bay-K-8644 (an activator of L-type $Ca^{2+}$ channels, 10 $\mu$ M) and cyclopiazonic acid (an inhibitor of cytoplasmic $Ca^{2+}-ATPase, 10 \mu$ M) were relative time-dependently attenuated. However, nicotine (30$\mu$ M), given into the adrenal gland for 60 min, initially rather enhanced CA secretory responses evoked by ACh and high $K^+$, followed by the inhibition later, while it time-dependently depressed the CA release evoked by McN-A-343 and DMPP. Taken together, these results suggest that cotinine inhibits greatly CA secretion evoked by stimulation of cholinergic (both nicotinic and muscarinic) receptors, but does fail to affect that by the direct membrane-depolarization. It seems that this inhibitory effect of cotinine may be exerted by the cholinergic blockade, which is associated with blocking both the calcium influx into the rat adrenal medullary chromaffin cells and $Ca^{2+}$ release from the cytoplasmic calcium store. It also seems that there is a big difference in the mode of action between cotinine and nicotine in the rat adrenomedullary CA secretion.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
제안 방법
There is a big controversy in the pharmacological actions of cotinine so far. Therefore, the present study was designed to clarify whether cotinine affects the release of catecholamines (CA) evoked by cholinergic stimulation and the membranedepolarization 1rom the perfused rat adrenal gland and to elucidate the mechanism of action, in comparison with the response of nicotine.
이론/모형
CA content of perf니sate was measured directly by the fluorcimetric method of Anton and Sayre (1962) without the intennediate purification alumina for the reasons described earlier ;Wakade, 1981) using fluorospectrophotometer (Koniron Co. Italy).
성능/효과
, 1998). Based on these previous facts, the present findings that continine relatively inhibited dose- and time- dependently CA secretory responses evoked by DMPP and McN-A-343 as well as by ACh from the perfused rat adrenal medulla suggest that this inhibitory effect of cotinine may be mediated by the blockade of cholinergic receptors located on the rat adrenomedullary chromaffin cells.
In conclusion, these resets suggest that cotinine inhibits CA secretion evoked by stimulation of cholinergic (both nicotinic and muscarinic) receptors, I기jt does fail to affect that by the direct membrane-depolarization. This inhibitory effect of cotinine is thought to be mediated by blocking both the calcium infl나x into the rat adrenal medullary chromaffin cells and Ca2+ release from the cytoplasmic calcium store, There also seems to be a big difference in the mode of action between cotinine and nicotine in rat adrenomedullary CA secretion.
In the preliminary experiments it was found that upon administration of the above dr니gs, secretory responses to ACh, KCI, McN-A-343, Bay-K-8644 and cyclopiazonic acid returned to pre-injection level in about 4 min, but the responses to DMPP in 8 min.
참고문헌 (52)
Akaike, A., Mine, Y., Sasa, M., and Takaori, S., Voltage and current clamp studies of muscarinic and nicotinic excitation of the rat adrenal chromaffin cells. J. Pharmacol. Expt. Ther., 255, 333-339 (1990)
Andersson, K., Jansson, A., Kuylenstierna, F., and Eneroth, P., Nicotine and its major metabolite cotinine have different effects on aldosterone and prolactin serum levels in he normal male rat. Eur. J. Pharmacol., 228, 305-312 (1993)
Anton, A. H. and Sayre, D. F., A study of the factors affecting the aluminum oxidetrihydroxy insole procedure for the analysis of catecholamines. J. Pharmacol. Exp. Ther., 138, 360-375 (1962)
Benowitz, N. L., Jacob, P., Fong, I., and Gupta, S., Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther., 268, 296-303 (1994)
Benowitz, N. L. and Jacob, P., Pharmacokinetics and metabolism of nicotine and related alkaloids: In Arneric, S.P. and Brioni, J.D. (Eds.). Neuronal Nicotinic Receptors. Pharmacology and Therapeutic Opportunities, Wiley-Liss, New York, pp. 213-234, (1999)
Benowitz, N. L., Kuyt, F., Jacob, P., Jones, R. T., and Osman, A. L., Cotinine disposition and effects. Clin. Pharmacol. Ther., 34, 604-611 (1983)
Borzelleca, J. F., Bowman, E. R., and McKennis, H. Jr., Studies on the respiratory and cardiovascular effects of (-)-cotinine. J. Pharmacol. Exp. Ther., 137, 313-318 (1962)
Chahine, R., Aftimos, G., Wainberg, M. C., Navarro-Delmasure, C., Abou Khalil, K., and Chahoud, B., Cotinine modulates the cardiovascular effects of nicotine. Med. Sci. Res., 24, 21-23 (1996)
Chahine, R., Calderone, A., and Navarro-Delmasure, C., The in vitro effects of nicotine and cotinine on prostacyclin and thromboxane biosynthesis. Prostaglandins Leukot Essent Fatty Acids, 40, 261-266 (1990)
Challiss, R. A. J., Jones, J. A., Owen, P. J., and Boarder, M. R., Changes in inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate mass accumulations in cultured adrenal chromaffin cells in response to bradykinin and histamine. J. Neurochem., 56, 1083-1086 (1991)
Cheek, T. R., O'Sullivan, A. J., Moreton, R. B., Berridge, M. J., and Burgoyne, R. D., Spatial localization of the stimulusinduced rise in cyrosolic $Ca^{2+}$ in bovine adrenal chromaffin cells: Distinct nicotinic and muscarinic patterns. FEBS Lett., 247, 429-434 (1989)
Crooks, P. A., Li, M., and Dwoskin, L. P., Metabolites of nicotine in rat brain after peripheral nicotine administration: Cotinine nornicotine and norcotinine. Drug Metab. Dispos., 25, 47-54 (1997)
Cryer, P. E., Haymond, M.W., Santiago, J. V., and Shah, S. D., Norepinephrine and epinephrine release and adrenergic mediation of smoking associated hemodynamic and metabolic events. N. Engl. J. Med., 295, 573-577 (1976)
Dar, M. S., Bowman, E. R., and Li, C., Intracerebellar nicotinic-cholinergic participation in the cerebella adesinoergic modulation of ethanol-induced motor incoordination in mice. Brain Res., 644, 117-127 (1994)
Douglas, W. W., Kanno, and Sampson, S. R., Influence of the ionic environment on the membrane potential of adrenal chromaffin cells and on the depolarizing effect of acetylcholine. J. Physiol., 191, 107-121 (1967)
Dwoskin, L. P., Teng, L., Buxton, S. T., and Crooks, P. A., S-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke $[^3H]$ dopamine release from rat striatal slices in acalcium-dependent manner. J. Pharmacol. Exp. Ther., 288, 905-911 (1999)
Erenmemisoglu, A. and Tekol, Y., Do nicotine metabolites have an effect on pain perception? Antinociceptive effect of cotinine in mice. Pharmazie, 49, 374-375 (1994)
Garcia, A. G., Sala, F., Reig, J. A., Viniegra, S., Frias, J., Fonteriz, R., and Gandia, L., Ihydropyridine Bay-K-8644 activates chromaffin cell calcium channels. Nature, 309, 69-71 (1984)
Garvey, A. J., Ward, K. D., Bliss, R. E., Rosner, B., and Vokonas, P. S., Relation between saliva cotinine concentration, cigarette consumption, and blood pressure among smokers. Am. J. cardiol., 76(1), 95-97 (1995)
Goeger, D. E. and Riley, R. T., Interaction of cyclopiazonic acid with rat skeletal muscle sarcoplasmic reticulum vesicles. Effect on $Ca^{2+}$ binding and $Ca^{2+}$ permeability. Biochem. Pharmacol., 38, 3995-4003 (1989)
Goldberg, S. R., Risner, M. E., Stolerman, I. P., Reavill, C., and Garcha, H. S., Nicotine and some related compounds: effects on schedule-controlled behavior and discriminative properties in rats. Psycho. pharmacology, 97, 265-302 (1989)
Gorrod, J. W. and Wahren, J., Nicotine and Related Alkaloids: Absorption, Distribution, Metabolism, Excretion. Chapman and Hall, London, (1993)
Hammer, R. and Giachetti, A., Muscarinic receptor subtypes: $M_1$ and $M_2$ biochemical and functional characterization. Life Sci., 31, 2992-2998 (1982)
Hatsukami, D. K., Grillo, M., Pentel, P. R., Oncken, C., and Bliss, R., Safety of cotinine in humans: physiologic, subjective and cognitive effects. Pharmacol. Biochem. Behav., 57, 643-650 (1997)
Hatsukami, D., Pentel, P. R., Jensen, J., Nelson, D., Allen, S. S., Goldman, A., and Rafael, D., Cotinine: effects with and without nicotine. Psychopharmacology, 135, 141-150 (1998)
Hurt, R. D., Dale, L. C., Offord, K. P., Lauger, G. G., Baskin, L. B., Lawson, G. M., Jiang, N. S., and Hauri, P. J., Serum nicotine and cotinine levels during nicotine-patch therapy. Clin. Pharmacol. Ther., 54, 98-106 (1993)
Keenan, R. M., Hatsukami, D. K., Pentel, P. R., Thompson, T. N., and Grillo, M. A., Pharmacodynamic effects of cotinine in abstinent cigarette smokers. Clin. Pharmacol. Ther., 55, 581-590 (1994)
Kilpatrick, D. L., Slepetis, R., and Kirshner, N., Ion channels and membrane potential in stimulus-secretion coupling in adrenal medulla cells. J. Neurochem., 36, 1245-1255 (1981)
Kim, K. S., Borzelleca, J. F., Bowman, E. R., and McKennis, H. Jr., Effects of some nicotine metabolites and related compounds on isolated smooth muscle. J. Pharmacol. Exp. Ther., 161, 59-69 (1968)
Ladona, M. G., Aunis, D., Gandia, A. G., and Garcia, A. G., Dihydropyridine modulation of the chromaffin cell secretory response. J. Neurochemstry, 48, 483-490 (1987)
Lim, D. Y. and Hwang, D.-H., Studies on secretion of catecholamines evoked by DMPP and McN-A-343 in the rat adrenal gland. Kor. J. Pharmacol., 27(1), 53-67 (1991)
Lim, D. Y., Kim, C.-D., and Ahn, K.-W., Influence of TMB-8 on secretion of catecholamines from the perfused rat adrenal glands. Arch. Pharm. Res., 15(2), 115-125 (1992)
Oka, M., Isosaki, M. and Yanagihara, N., Isolated bovine adrenal medullary cells: studies on regulation of catecholamine synthesis and release: In Catecholamines: Basic and Clinical frontiers (Eds. Usdin, E., Kopin, I. J., and Brachas, J.). Pergamon Press, Oxford, pp. 70-72, (1979)
Patterson, T. R., Stringham, J. D., and Meikle, A. W., Nicotine and cotinine inhibit steroidogenesis in mouse Leydig cells. Life Sci., 46, 265-272 (1990)
Pinto, J. E. B. and Trifaro, J. M., The different effects of D-600 (methoxyverapamil) on the release of adrenal catecholamines induced by acetylcholine, high potassium or sodium deprivation. Brit. J. Pharmacol., 57, 127-132 (1976)
Saareks, V., Riutta, A., Mucha, I., Alanko, J., and Vapaatalo, H., Nicotine and cotinine modulate eicosanoid production in human leukocytes and platelet rich plasma. Eur. J. Pharmacol., 248(4), 345-349 (1993)
Sastry, B. V. R., Chance, M. B., Singh, G., Horn, J. L., and Janson, V. E., Distribution and retention of nicotine and its metabolite, cotinine, in the rat as a function of time. Pharmacology, 50, 128-136 (1995)
Schramm, M., Thomas, G., Towart, R., and Franckowiak, G., Novel dihydropyridines with positive isotropic action through activation of $Ca^{2+}$ channels. Nature, 303, 535-537 (1982)
Seidler, N. W., Jona, I., Vegh, N., and Martonosi, A., Cyclopiazonic acid is a specific inhibitor of the $Ca^{2+}$ -ATPase of sarcoplasimc reticulum. J. Biol. Chem., 264, 17816-17823 (1989)
Shoaib, M. and Stolerman, I. P., Plasma nicotine and cotinine levels following intravenous nicotine self-administration in rats. Psychopharmacology, (Berl) 143(3), 318-321 (1999)
Suzuki, M., Muraki, K., Imaizumi, Y., and Watanabe, M., Cyclopiazonic acid, an inhibitor of the sarcoplasmic reticulum $Ca^{2+}$ -pump, reduces $Ca^{2+}$ -dependent $K^+$ currents in guineapig smooth muscle cells. Br. J. Pharmacol., 107, 134-140 (1992)
Takada, K., Swedberg, M. D., Goldberg, S. R., and Katz, J. L., Discriminative stimulus effects effects of intravenous 1-nicotine analogs or metabolites in squirrel monkeys. Psycho. pharmacology, 99, 208-212 (1989)
Tallarida, R. J. and Murray, R. B., Manual of pharmacologic calculation with computer programs. 2nd Ed New York Speringer-Verlag, pp. 132, (1987)
Uceda, G., Artalejo, A. R., Lopez, M. G., Abad, F., Neher, E., and Garcia, A. G., $Ca^{2+}$ -activated $K^+$ channels modulated muscarinic secretion in ca chromaffin cells. J. Physical., 454, 213-230 (1992)
Uyama, Y., Imaizumi, Y., and Watanabe, M., Effects of cyclopiazonic acid, a novel $Ca^{2+}$ -ATPase inhibitor on contractile responses in skinned ideal smooth muscle. Br. J. Pharmacol., 106, 208-214 (1992)
Vainio, P. J., Vilusksela, M., and Tuominen, R.K., Inhibition of nicotinic by cotinine in bovine adrenal chromaffin cells. Pharmacol. Toxical., 83, 188-193 (1998)
Wada, Y., Satoh, K., and Taira, N., Cardiovascular profile of Bay-K-8644, a presumed calcium channel activator in the dog. Naunyn-Schmiedebergs Arch. Pharmacol., 328, 382-387 (1985)
Wakade, A. R., Studies on secretion of catecholamines evoked by acetylcholine or transmural stimulation of the rat adrenal gland. J. Physiol., 313, 463-480 (1981)
Winders, S. E., Grunberg, N. E., Benowitz, N. L., and Alvares, A.P., Effects of stress on circulating nicotine and cotinine levels and in vitro nicotine metabolism in the rat. Psychopharmacology, 137, 383-390 (1998)
Yeh, J., Barbieri, R. J., and Friedman, A. J., Nicotine and cotinine inhibit rat testes androgen biosynthesis in vitro. Steroid Biochem., 33, 627-630 (1989)
※ AI-Helper는 부적절한 답변을 할 수 있습니다.